Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074231 | 1.00 | TACR1 (0.62) | TACR1CYP2D6KCNH2 | |
| SCHEMBL6228274 | 0.96 | TACR1 (0.62) | TACR1CYP2D6 | |
| SCHEMBL6228277 | 0.96 | TACR1 (0.62) | TACR1CYP2D6 | |
| SCHEMBL6233827 | 0.92 | TACR1 (0.61) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7599484 | 0.91 | TACR1 (0.60) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6227539 | 0.91 | TACR1 (0.60) | TACR1CYP2D6 | |
| SCHEMBL6452148 | 0.91 | TACR1 (0.58) | TACR1CYP2D6 | |
| SCHEMBL6073720 | 0.89 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL6073522 | 0.89 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL7118326 | 0.89 | TACR1 (0.61) | TACR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | claimed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR1 1/4885CYP2D6 1499/4885KCNH2 182/4885 |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | TACR1 187/4885CYP2D6 471/4885KCNH2 879/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1323/4885KCNH2 158/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | TACR1 5/4885CYP2D6 1204/4885KCNH2 158/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | TACR1 187/4885CYP2D6 471/4885KCNH2 879/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | TACR1 1/4885CYP2D6 2736/4885KCNH2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.